Phase I oncology trials: risks and benefits vary by trial type

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2005年 / 1042卷 / 1期
关键词：
Public Health; Toxic Event; Cancer Therapy; Chemotherapeutic Agent; Stable Disease;
D O I：
10.2165/00128415-200510420-00010
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5 / 5
相关论文
共 50 条
  • [1] Communication about the risks and benefits of phase I pediatric oncology trials
    Hazen, Rebecca A.
    Zyzanski, Stephen
    Baker, Justin N.
    Drotar, Dennis
    Kodish, Eric
    CONTEMPORARY CLINICAL TRIALS, 2015, 41 : 139 - 145
  • [2] Benefits (survival) and risks (30 days mortality) of phase I trials in oncology
    Djulbegovic, B.
    Moreno, C.
    Kumar, A.
    Lush, R.
    Munster, P. N.
    Daud, A. I.
    Garrett, C. R.
    Simon, G. R.
    Lancet, J. E.
    Sullivan, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Risks and benefits of phase 1 oncology trials, revisited
    Kurzrock, R
    Benjamin, RS
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (09): : 930 - 932
  • [4] Clinical benefits and risks of phase I oncology trials: experience from a single institution
    Gollamudi, R.
    Wong, B. M.
    Ghalib, M. H.
    Kumar, M.
    Desai, K.
    Chaudhary, I.
    Goel, S.
    Mani, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Risks and benefits of phase 1 oncology trials, 1991 through 2002
    Horstmann, E
    McCabe, MS
    Grochow, L
    Yamamoto, S
    Rubinstein, L
    Budd, T
    Shoemaker, D
    Emanuel, EJ
    Grady, C
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (09): : 895 - 904
  • [6] Risks and benefits of phase 1 oncology trials in the era of personalized medicine
    Chakiba, Camille
    Grellety, Thomas
    Cousin, Sophie
    Italiano, Antoine
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Descriptions of benefits and risks in consent forms for phase 1 oncology trials
    Horng, S
    Emanuel, EJ
    Wilfond, B
    Rackoff, J
    Martz, K
    Grady, C
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (26): : 2134 - 2140
  • [8] Risks and benefits of phase 1 oncology trials in the era of personalized medicine
    Chakiba, C.
    Grellety, T.
    Cousin, S.
    Italiano, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Risks and benefits associated with novel phase 1 oncology trial designs
    Koyfman, Shlomo A.
    Agrawal, Manish
    Garreft-Mayer, Elizabeth
    Krohmal, Benjamin
    Wolf, Elizabeth
    Emanuel, Ezekiel J.
    Gross, Cary P.
    CANCER, 2007, 110 (05) : 1115 - 1124
  • [10] Risks and benefits of phase 1 oncology trials, 2001 through 2012.
    Fukuda, Yoko Korenaga
    Huang, Erich
    Finnigan, Shanda
    Ivy, S. Percy
    Rubinstein, Larry
    Takebe, Naoko
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345